<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02433977</url>
  </required_header>
  <id_info>
    <org_study_id>PRO14110207</org_study_id>
    <nct_id>NCT02433977</nct_id>
  </id_info>
  <brief_title>The Effects of NOx and Conjugated Linoleic Acid on Asthmatics</brief_title>
  <acronym>NICLA</acronym>
  <official_title>A Proof of Concept Study to Determine the Effects of NOX and Conjugated Linoleic Acid on Asthmatics</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gladwin, Mark, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Pittsburgh</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will examine the hypothesis that in obese asthmatics; treatment with NOx + CLA is&#xD;
      well tolerated, safe and will increase eNO while reducing airway oxidative stress. Allied&#xD;
      with this, the investigators will define whether supplementing with this bioactive mediator&#xD;
      modifies the airway microbiome, and reduces airway inflammation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Obesity is an asthma comorbidity associated with increased severity, poor control, reduced&#xD;
      steroid responsiveness and greater exacerbation and healthcare utilization rates. These&#xD;
      associations are not explained by having a greater degree of Th-2 inflammation. Rather, the&#xD;
      obese asthma phenotype defined in several cluster studies, has paradoxically reduced levels&#xD;
      of Th-2 biomarkers, including sputum eosinophils and exhaled nitric oxide (NO). The&#xD;
      investigators previous research has shown that the inverse relation between increased body&#xD;
      mass index (BMI) and reduced exhaled NO, may be explained by a metabolic imbalance&#xD;
      characterized by lower L-arginine and greater asymmetric di-methyl arginine (ADMA) levels.&#xD;
      Having a low L-arginine/ADMA ratio has been shown to inhibit and uncouple all isoforms of&#xD;
      nitric oxidase synthase (NOS), thereby reducing NO bioavailability and promoting oxidative&#xD;
      stress through enhanced superoxide production. In obese asthmatics, this imbalance not only&#xD;
      correlates with exhaled NO, but also with lower FEV1% and poorer asthma-related quality of&#xD;
      life. Yet the effect of obesity in asthma is unlikely to be solely dependent on a single&#xD;
      mechanism. Other factors, such as increased Th1 and Th-17-mediated inflammation have been&#xD;
      shown to occur in human and animal models. Given all of these potential avenues, it is&#xD;
      imperative that an intervention is sufficiently pleiotropic that can, in addition to&#xD;
      restoring airway NO levels, also reduce other obesity-related non-Th2 mechanism of&#xD;
      inflammation. The investigators hypothesize that treatment with conjugated linolenic acid&#xD;
      (CLA) + nitrate and nitrite (together known as NOx), will restore NO airway bioavailability,&#xD;
      reduce oxidative stress and improve airway inflammation in obese asthmatics. To test this&#xD;
      hypothesis, the investigators propose a phase II pilot study in which obese asthmatics with&#xD;
      metabolic syndrome, will be treated orally with CLA+NOx for 8 weeks, in an open label study&#xD;
      design to assess pre to post-intervention changes in airway and systemic biomarkers, and to&#xD;
      determine the effects on lung function and bronchial hyperresponsiveness. Participants will&#xD;
      undergo a pre and post intervention bronchoscopy. The results obtained from this project will&#xD;
      be greatly informative to our understanding of the obese - asthma pathophysiology and for the&#xD;
      development of clinical trials to determine the potential benefit of this intervention in&#xD;
      improving health outcomes.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 2015</start_date>
  <completion_date type="Actual">November 2019</completion_date>
  <primary_completion_date type="Actual">November 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Exhaled NO Before and After Treatment</measure>
    <time_frame>Before treatment at baseline and after treatment at 8 weeks</time_frame>
    <description>Determine how CLA and NOx affect airway NO bioavailability (exhaled NO)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Biomarkers of Inflammation-bronchial Hyperresponsiveness Using PC20</measure>
    <time_frame>Before treatment at baseline and after treatment at 8 weeks</time_frame>
    <description>To determine whether, compared to baseline, treatment with NOx + CLA can reduce bronchial hyperresponsiveness. PC20 was measured by methacholine challenge (mg/mL) in three participants pre and post supplementation with Nitrate/Nitrite and cLA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarkers of Inflammation- Concentration of Free CLA in Plasma</measure>
    <time_frame>Before treatment at baseline and after treatment at 8 weeks</time_frame>
    <description>To determine whether, compared to baseline, treatment with NOx + CLA can quantify the concentrations of free CLA in plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With an Increase in IL-6 and IL-1b Expression</measure>
    <time_frame>Before treatment at baseline and after treatment at 8 weeks</time_frame>
    <description>To determine whether, compared to baseline, treatment with NOx + CLA will increase a participant's IL-6 and IL-1b expression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarkers of Inflammation-airway XO Activity</measure>
    <time_frame>Before treatment at baseline and after treatment at 8 weeks</time_frame>
    <description>To determine whether, compared to baseline, treatment with NOx + CLA can effect airway XO activity determined in endobronchial biopsies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarkers of Inflammation-15NO2-cLA</measure>
    <time_frame>Before treatment at baseline and after treatment at 8 weeks</time_frame>
    <description>To determine whether, compared to baseline, treatment with NOx + CLA can effect measurement of 15NO2-cLA in urine.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarkers of Inflammation-anion Superoxide</measure>
    <time_frame>Before treatment at baseline and after treatment at 8 weeks</time_frame>
    <description>To determine whether, compared to baseline, treatment with NOx + CLA can decrease production of anion superoxide in fresh airway epithelial cells</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With a Decrease of Inflammation Using Mitochondrial ROS Production</measure>
    <time_frame>Before treatment at baseline and after treatment at 8 weeks</time_frame>
    <description>To determine whether, compared to baseline, treatment with NOx + CLA can decrease inflammation using mitochondrial ROS production in fresh and cultured airway epithelial cells.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarkers of Inflammation- Concentration of NO2-CLA in Plasma</measure>
    <time_frame>Before treatment at baseline and after treatment at 8 weeks</time_frame>
    <description>To determine whether, compared to baseline, treatment with NOx + CLA can quantify the concentrations of NO2-cLA in plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarkers of Inflammation- Concentration of NO2-CLA in Urine</measure>
    <time_frame>Before treatment at baseline and after treatment at 8 weeks</time_frame>
    <description>To determine whether, compared to baseline, treatment with NOx + CLA can quantify the concentrations of NO2-cLA in urine</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Conjugated Linolenic Acid + NOx</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This is a single arm study&#xD;
Conjugated Linolenic Acid (CLA)- daily oral dose 3 g/day&#xD;
Sodium Nitrate- Capsules for daily oral administration at the dose of 1 g (2 x 500 mg)&#xD;
Sodium Nitrite- Capsules for daily oral administration at the dose of 20 mg (2 x 10 mg)</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Conjugated Linolenic Acid</intervention_name>
    <description>CLA is a polyunsaturated fatty acid Subjects will receive capsules for daily oral administration at the dose of 3 g/day</description>
    <arm_group_label>Conjugated Linolenic Acid + NOx</arm_group_label>
    <other_name>conjugated linolenic acid (CLA)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sodium Nitrite</intervention_name>
    <description>Subjects will receive capsules for daily oral administration at the dose of 20 mg (2 x 10 mg)</description>
    <arm_group_label>Conjugated Linolenic Acid + NOx</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sodium Nitrate</intervention_name>
    <description>Subjects will receive capsules for daily oral administration at the dose of 1g (2 x 500 mg)</description>
    <arm_group_label>Conjugated Linolenic Acid + NOx</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adequate completion of informed consent process with written documentation&#xD;
&#xD;
          -  Male and female patients, ≥ 18 - 65 yrs old&#xD;
&#xD;
          -  Diagnosis of asthma: based on previous physician diagnosis and either baseline&#xD;
             pre-bronchodilator FEV1 50% or greater predicted with a 12% or greater bronchodilator&#xD;
             response to 4 puffs of albuterol or PC20 methacholine (16 mg) if no BD response.If the&#xD;
             subject is not currently on an ICS/ ICS LABA, PC20 should be &lt; 8 mg, if no BD&#xD;
             response. Spirometry results within the prior 24 months located in the subject's&#xD;
             medical records can be used to determine eligibility, if available.&#xD;
&#xD;
          -  All racial/ethnic backgrounds with a diagnosis of asthma for ≥6 months&#xD;
&#xD;
          -  Smoking history ≤10 pack years and no smoking in the last year&#xD;
&#xD;
          -  BMI ≥ 30&#xD;
&#xD;
          -  If subject is on ICS or ICS/LABA therapy- 30 days on a stable dose (up to 1,000 mcg&#xD;
             daily fluticasone equivalent)&#xD;
&#xD;
          -  Asthma diagnosed at age 9 or later&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Respiratory tract infection within the last 4 weeks&#xD;
&#xD;
          -  Oral or systemic CS burst within the last 4 weeks&#xD;
&#xD;
          -  Asthma-related hospitalization within the last 2 months&#xD;
&#xD;
          -  Asthma-related ER visit within the previous 4 weeks&#xD;
&#xD;
          -  Significant or uncontrolled concomitant medical illness including (but not limited to)&#xD;
             heart disease, cancer, diabetes&#xD;
&#xD;
          -  Chronic renal failure (creatinine &gt; 2.0) at screening (Associated with higher ADMA&#xD;
             levels)&#xD;
&#xD;
          -  Current statins use (statins lower ADMA levels), patients may stop and re-enroll after&#xD;
             2 weeks of stopping statins&#xD;
&#xD;
          -  Positive pregnancy test&#xD;
&#xD;
          -  Intolerance or allergy to the intervention drugs&#xD;
&#xD;
          -  Current or recent (within 30 days) in an investigational treatment study.&#xD;
&#xD;
          -  Unable or unlikely to complete study assessments or the study intervention (i.e.&#xD;
             bronchoscopy) poses undue risk to patient in the opinion of the Investigator.&#xD;
&#xD;
          -  Any kind of oral nitrates such as nitroglycerin or already taking supplements&#xD;
&#xD;
          -  History of ICU admission/intubation due to asthma in the past year;&#xD;
&#xD;
          -  More than three systemic corticosteroid requiring asthma exacerbations in the past&#xD;
             year&#xD;
&#xD;
          -  Systemic steroid dependent asthma (no daily oral steroids- short term therapy for&#xD;
             asthma exacerbation is permitted)&#xD;
&#xD;
          -  Use of mouthwash containing chlorhexidine (lowers NO) within 1 week prior to screening&#xD;
             and throughout the study&#xD;
&#xD;
          -  Untreated sleep apnea&#xD;
&#xD;
          -  Hgb A1C ≥7&#xD;
&#xD;
          -  Daily use of PPI's (Proton Pump Inhibitor) or H2 Blockers for GERD (it is permitted to&#xD;
             take on an occasional basis- no more than 1x per week. If participants wash out of&#xD;
             these meds for 1 week, they can enroll)&#xD;
&#xD;
          -  Use of biologics for asthma/allergies unless there is a 4 month washout prior to&#xD;
             enrollment (the washout for biologics is done for clinical reasons and not&#xD;
             specifically for inclusion for the study).&#xD;
&#xD;
          -  Drug and/or alcohol abuse for ≥1 year&#xD;
&#xD;
          -  Breastfeeding&#xD;
&#xD;
          -  Any other condition and/or situation that causes the investigator to deem a subject&#xD;
             unsuitable for the study (e.g. due to expected study medication non-compliance,&#xD;
             inability to medically tolerate the study procedures, or a subject's unwillingness to&#xD;
             comply with study-related procedures.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sally E Wenzel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Pittsburgh Asthma Institute at UPMC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The University of Pittsburgh Asthma Institute at UPMC</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>December 11, 2014</study_first_submitted>
  <study_first_submitted_qc>April 29, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 5, 2015</study_first_posted>
  <results_first_submitted>November 25, 2020</results_first_submitted>
  <results_first_submitted_qc>March 2, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">March 26, 2021</results_first_posted>
  <last_update_submitted>April 5, 2021</last_update_submitted>
  <last_update_submitted_qc>April 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Pittsburgh</investigator_affiliation>
    <investigator_full_name>Sally E. Wenzel MD</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Asthma</keyword>
  <keyword>Obesity</keyword>
  <keyword>conjugated linolenic acid</keyword>
  <keyword>nitrate</keyword>
  <keyword>nitrite</keyword>
  <keyword>nutritional supplements</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>December 11, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/77/NCT02433977/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Conjugated Linolenic Acid + NOx</title>
          <description>This is a single arm study&#xD;
Conjugated Linolenic Acid (CLA)- daily oral dose 3 g/day&#xD;
Sodium Nitrate- Capsules for daily oral administration at the dose of 1 g (2 x 500 mg)&#xD;
Sodium Nitrite- Capsules for daily oral administration at the dose of 20 mg (2 x 10 mg)&#xD;
Conjugated Linolenic Acid: CLA is a polyunsaturated fatty acid Subjects will receive capsules for daily oral administration at the dose of 3 g/day&#xD;
Sodium Nitrite: Subjects will receive capsules for daily oral administration at the dose of 20 mg (2 x 10 mg)&#xD;
Sodium Nitrate: Subjects will receive capsules for daily oral administration at the dose of 1g (2 x 500 mg)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Conjugated Linolenic Acid + NOx</title>
          <description>This is a single arm study&#xD;
Conjugated Linolenic Acid (CLA)- daily oral dose 3 g/day&#xD;
Sodium Nitrate- Capsules for daily oral administration at the dose of 1 g (2 x 500 mg)&#xD;
Sodium Nitrite- Capsules for daily oral administration at the dose of 20 mg (2 x 10 mg)&#xD;
Conjugated Linolenic Acid: CLA is a polyunsaturated fatty acid Subjects will receive capsules for daily oral administration at the dose of 3 g/day&#xD;
Sodium Nitrite: Subjects will receive capsules for daily oral administration at the dose of 20 mg (2 x 10 mg)&#xD;
Sodium Nitrate: Subjects will receive capsules for daily oral administration at the dose of 1g (2 x 500 mg)</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40.5" spread="10.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Exhaled NO Before and After Treatment</title>
        <description>Determine how CLA and NOx affect airway NO bioavailability (exhaled NO)</description>
        <time_frame>Before treatment at baseline and after treatment at 8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Conjugated Linolenic Acid + NOx</title>
            <description>This is a single arm study&#xD;
Conjugated Linolenic Acid (CLA)- daily oral dose 3 g/day&#xD;
Sodium Nitrate- Capsules for daily oral administration at the dose of 1 g (2 x 500 mg)&#xD;
Sodium Nitrite- Capsules for daily oral administration at the dose of 20 mg (2 x 10 mg)&#xD;
Conjugated Linolenic Acid: CLA is a polyunsaturated fatty acid Subjects will receive capsules for daily oral administration at the dose of 3 g/day&#xD;
Sodium Nitrite: Subjects will receive capsules for daily oral administration at the dose of 20 mg (2 x 10 mg)&#xD;
Sodium Nitrate: Subjects will receive capsules for daily oral administration at the dose of 1g (2 x 500 mg)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Exhaled NO Before and After Treatment</title>
          <description>Determine how CLA and NOx affect airway NO bioavailability (exhaled NO)</description>
          <units>parts per billion</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.5" spread="10.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;=0.05</p_value>
            <method>t-test, 1 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Biomarkers of Inflammation-bronchial Hyperresponsiveness Using PC20</title>
        <description>To determine whether, compared to baseline, treatment with NOx + CLA can reduce bronchial hyperresponsiveness. PC20 was measured by methacholine challenge (mg/mL) in three participants pre and post supplementation with Nitrate/Nitrite and cLA</description>
        <time_frame>Before treatment at baseline and after treatment at 8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Conjugated Linolenic Acid + NOx</title>
            <description>This is a single arm study&#xD;
Conjugated Linolenic Acid (CLA)- daily oral dose 3 g/day&#xD;
Sodium Nitrate- Capsules for daily oral administration at the dose of 1 g (2 x 500 mg)&#xD;
Sodium Nitrite- Capsules for daily oral administration at the dose of 20 mg (2 x 10 mg)&#xD;
Conjugated Linolenic Acid: CLA is a polyunsaturated fatty acid Subjects will receive capsules for daily oral administration at the dose of 3 g/day&#xD;
Sodium Nitrite: Subjects will receive capsules for daily oral administration at the dose of 20 mg (2 x 10 mg)&#xD;
Sodium Nitrate: Subjects will receive capsules for daily oral administration at the dose of 1g (2 x 500 mg)</description>
          </group>
        </group_list>
        <measure>
          <title>Biomarkers of Inflammation-bronchial Hyperresponsiveness Using PC20</title>
          <description>To determine whether, compared to baseline, treatment with NOx + CLA can reduce bronchial hyperresponsiveness. PC20 was measured by methacholine challenge (mg/mL) in three participants pre and post supplementation with Nitrate/Nitrite and cLA</description>
          <units>mg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.33" spread="12.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;=0.05</p_value>
            <method>t-test, 1 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Biomarkers of Inflammation- Concentration of Free CLA in Plasma</title>
        <description>To determine whether, compared to baseline, treatment with NOx + CLA can quantify the concentrations of free CLA in plasma</description>
        <time_frame>Before treatment at baseline and after treatment at 8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Conjugated Linolenic Acid + NOx</title>
            <description>This is a single arm study&#xD;
Conjugated Linolenic Acid (CLA)- daily oral dose 3 g/day&#xD;
Sodium Nitrate- Capsules for daily oral administration at the dose of 1 g (2 x 500 mg)&#xD;
Sodium Nitrite- Capsules for daily oral administration at the dose of 20 mg (2 x 10 mg)&#xD;
Conjugated Linolenic Acid: CLA is a polyunsaturated fatty acid Subjects will receive capsules for daily oral administration at the dose of 3 g/day&#xD;
Sodium Nitrite: Subjects will receive capsules for daily oral administration at the dose of 20 mg (2 x 10 mg)&#xD;
Sodium Nitrate: Subjects will receive capsules for daily oral administration at the dose of 1g (2 x 500 mg)</description>
          </group>
        </group_list>
        <measure>
          <title>Biomarkers of Inflammation- Concentration of Free CLA in Plasma</title>
          <description>To determine whether, compared to baseline, treatment with NOx + CLA can quantify the concentrations of free CLA in plasma</description>
          <units>Nanomolar</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="161.8" spread="44.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;=0.05</p_value>
            <method>t-test, 1 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With an Increase in IL-6 and IL-1b Expression</title>
        <description>To determine whether, compared to baseline, treatment with NOx + CLA will increase a participant's IL-6 and IL-1b expression.</description>
        <time_frame>Before treatment at baseline and after treatment at 8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Conjugated Linolenic Acid + NOx</title>
            <description>This is a single arm study&#xD;
Conjugated Linolenic Acid (CLA)- daily oral dose 3 g/day&#xD;
Sodium Nitrate- Capsules for daily oral administration at the dose of 1 g (2 x 500 mg)&#xD;
Sodium Nitrite- Capsules for daily oral administration at the dose of 20 mg (2 x 10 mg)&#xD;
Conjugated Linolenic Acid: CLA is a polyunsaturated fatty acid Subjects will receive capsules for daily oral administration at the dose of 3 g/day&#xD;
Sodium Nitrite: Subjects will receive capsules for daily oral administration at the dose of 20 mg (2 x 10 mg)&#xD;
Sodium Nitrate: Subjects will receive capsules for daily oral administration at the dose of 1g (2 x 500 mg)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With an Increase in IL-6 and IL-1b Expression</title>
          <description>To determine whether, compared to baseline, treatment with NOx + CLA will increase a participant's IL-6 and IL-1b expression.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;=0.05</p_value>
            <method>t-test, 1 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Biomarkers of Inflammation-airway XO Activity</title>
        <description>To determine whether, compared to baseline, treatment with NOx + CLA can effect airway XO activity determined in endobronchial biopsies</description>
        <time_frame>Before treatment at baseline and after treatment at 8 weeks</time_frame>
        <population>Data were not collected for this Outcome Measure. The proposed aims could not be addressed with scientific rigor since the number of subjects who completed the study was very low.</population>
        <group_list>
          <group group_id="O1">
            <title>Conjugated Linolenic Acid + NOx</title>
            <description>This is a single arm study&#xD;
Conjugated Linolenic Acid (CLA)- daily oral dose 3 g/day&#xD;
Sodium Nitrate- Capsules for daily oral administration at the dose of 1 g (2 x 500 mg)&#xD;
Sodium Nitrite- Capsules for daily oral administration at the dose of 20 mg (2 x 10 mg)&#xD;
Conjugated Linolenic Acid: CLA is a polyunsaturated fatty acid Subjects will receive capsules for daily oral administration at the dose of 3 g/day&#xD;
Sodium Nitrite: Subjects will receive capsules for daily oral administration at the dose of 20 mg (2 x 10 mg)&#xD;
Sodium Nitrate: Subjects will receive capsules for daily oral administration at the dose of 1g (2 x 500 mg)</description>
          </group>
        </group_list>
        <measure>
          <title>Biomarkers of Inflammation-airway XO Activity</title>
          <description>To determine whether, compared to baseline, treatment with NOx + CLA can effect airway XO activity determined in endobronchial biopsies</description>
          <population>Data were not collected for this Outcome Measure. The proposed aims could not be addressed with scientific rigor since the number of subjects who completed the study was very low.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Biomarkers of Inflammation-15NO2-cLA</title>
        <description>To determine whether, compared to baseline, treatment with NOx + CLA can effect measurement of 15NO2-cLA in urine.</description>
        <time_frame>Before treatment at baseline and after treatment at 8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Conjugated Linolenic Acid + NOx</title>
            <description>This is a single arm study&#xD;
Conjugated Linolenic Acid (CLA)- daily oral dose 3 g/day&#xD;
Sodium Nitrate- Capsules for daily oral administration at the dose of 1 g (2 x 500 mg)&#xD;
Sodium Nitrite- Capsules for daily oral administration at the dose of 20 mg (2 x 10 mg)&#xD;
Conjugated Linolenic Acid: CLA is a polyunsaturated fatty acid Subjects will receive capsules for daily oral administration at the dose of 3 g/day&#xD;
Sodium Nitrite: Subjects will receive capsules for daily oral administration at the dose of 20 mg (2 x 10 mg)&#xD;
Sodium Nitrate: Subjects will receive capsules for daily oral administration at the dose of 1g (2 x 500 mg)</description>
          </group>
        </group_list>
        <measure>
          <title>Biomarkers of Inflammation-15NO2-cLA</title>
          <description>To determine whether, compared to baseline, treatment with NOx + CLA can effect measurement of 15NO2-cLA in urine.</description>
          <units>nmoles/mg creatinine</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.32" spread="8.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;=0.05</p_value>
            <method>t-test, 1 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Biomarkers of Inflammation-anion Superoxide</title>
        <description>To determine whether, compared to baseline, treatment with NOx + CLA can decrease production of anion superoxide in fresh airway epithelial cells</description>
        <time_frame>Before treatment at baseline and after treatment at 8 weeks</time_frame>
        <population>Data were not collected for this Outcome Measure. The proposed aims could not be addressed with scientific rigor since the number of subjects who completed the study was very low.</population>
        <group_list>
          <group group_id="O1">
            <title>Conjugated Linolenic Acid + NOx</title>
            <description>This is a single arm study&#xD;
Conjugated Linolenic Acid (CLA)- daily oral dose 3 g/day&#xD;
Sodium Nitrate- Capsules for daily oral administration at the dose of 1 g (2 x 500 mg)&#xD;
Sodium Nitrite- Capsules for daily oral administration at the dose of 20 mg (2 x 10 mg)&#xD;
Conjugated Linolenic Acid: CLA is a polyunsaturated fatty acid Subjects will receive capsules for daily oral administration at the dose of 3 g/day&#xD;
Sodium Nitrite: Subjects will receive capsules for daily oral administration at the dose of 20 mg (2 x 10 mg)&#xD;
Sodium Nitrate: Subjects will receive capsules for daily oral administration at the dose of 1g (2 x 500 mg)</description>
          </group>
        </group_list>
        <measure>
          <title>Biomarkers of Inflammation-anion Superoxide</title>
          <description>To determine whether, compared to baseline, treatment with NOx + CLA can decrease production of anion superoxide in fresh airway epithelial cells</description>
          <population>Data were not collected for this Outcome Measure. The proposed aims could not be addressed with scientific rigor since the number of subjects who completed the study was very low.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With a Decrease of Inflammation Using Mitochondrial ROS Production</title>
        <description>To determine whether, compared to baseline, treatment with NOx + CLA can decrease inflammation using mitochondrial ROS production in fresh and cultured airway epithelial cells.</description>
        <time_frame>Before treatment at baseline and after treatment at 8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Conjugated Linolenic Acid + NOx</title>
            <description>This is a single arm study&#xD;
Conjugated Linolenic Acid (CLA)- daily oral dose 3 g/day&#xD;
Sodium Nitrate- Capsules for daily oral administration at the dose of 1 g (2 x 500 mg)&#xD;
Sodium Nitrite- Capsules for daily oral administration at the dose of 20 mg (2 x 10 mg)&#xD;
Conjugated Linolenic Acid: CLA is a polyunsaturated fatty acid Subjects will receive capsules for daily oral administration at the dose of 3 g/day&#xD;
Sodium Nitrite: Subjects will receive capsules for daily oral administration at the dose of 20 mg (2 x 10 mg)&#xD;
Sodium Nitrate: Subjects will receive capsules for daily oral administration at the dose of 1g (2 x 500 mg)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With a Decrease of Inflammation Using Mitochondrial ROS Production</title>
          <description>To determine whether, compared to baseline, treatment with NOx + CLA can decrease inflammation using mitochondrial ROS production in fresh and cultured airway epithelial cells.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;=0.05</p_value>
            <method>t-test, 1 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Biomarkers of Inflammation- Concentration of NO2-CLA in Plasma</title>
        <description>To determine whether, compared to baseline, treatment with NOx + CLA can quantify the concentrations of NO2-cLA in plasma</description>
        <time_frame>Before treatment at baseline and after treatment at 8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Conjugated Linolenic Acid + NOx</title>
            <description>This is a single arm study&#xD;
Conjugated Linolenic Acid (CLA)- daily oral dose 3 g/day&#xD;
Sodium Nitrate- Capsules for daily oral administration at the dose of 1 g (2 x 500 mg)&#xD;
Sodium Nitrite- Capsules for daily oral administration at the dose of 20 mg (2 x 10 mg)&#xD;
Conjugated Linolenic Acid: CLA is a polyunsaturated fatty acid Subjects will receive capsules for daily oral administration at the dose of 3 g/day&#xD;
Sodium Nitrite: Subjects will receive capsules for daily oral administration at the dose of 20 mg (2 x 10 mg)&#xD;
Sodium Nitrate: Subjects will receive capsules for daily oral administration at the dose of 1g (2 x 500 mg)</description>
          </group>
        </group_list>
        <measure>
          <title>Biomarkers of Inflammation- Concentration of NO2-CLA in Plasma</title>
          <description>To determine whether, compared to baseline, treatment with NOx + CLA can quantify the concentrations of NO2-cLA in plasma</description>
          <units>Nanomolar</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.65" spread="1.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;=0.05</p_value>
            <method>t-test, 1 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Biomarkers of Inflammation- Concentration of NO2-CLA in Urine</title>
        <description>To determine whether, compared to baseline, treatment with NOx + CLA can quantify the concentrations of NO2-cLA in urine</description>
        <time_frame>Before treatment at baseline and after treatment at 8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Conjugated Linolenic Acid + NOx</title>
            <description>This is a single arm study&#xD;
Conjugated Linolenic Acid (CLA)- daily oral dose 3 g/day&#xD;
Sodium Nitrate- Capsules for daily oral administration at the dose of 1 g (2 x 500 mg)&#xD;
Sodium Nitrite- Capsules for daily oral administration at the dose of 20 mg (2 x 10 mg)&#xD;
Conjugated Linolenic Acid: CLA is a polyunsaturated fatty acid Subjects will receive capsules for daily oral administration at the dose of 3 g/day&#xD;
Sodium Nitrite: Subjects will receive capsules for daily oral administration at the dose of 20 mg (2 x 10 mg)&#xD;
Sodium Nitrate: Subjects will receive capsules for daily oral administration at the dose of 1g (2 x 500 mg)</description>
          </group>
        </group_list>
        <measure>
          <title>Biomarkers of Inflammation- Concentration of NO2-CLA in Urine</title>
          <description>To determine whether, compared to baseline, treatment with NOx + CLA can quantify the concentrations of NO2-cLA in urine</description>
          <units>nmoles/mg creatinine</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.33" spread="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;=0.05</p_value>
            <method>t-test, 1 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Before treatment at baseline through completion of treatment at 8 weeks</time_frame>
      <desc>The occurrence of adverse events was routinely determined through regular investigator/research coordinator assessment.</desc>
      <group_list>
        <group group_id="E1">
          <title>Conjugated Linolenic Acid + NOx</title>
          <description>This is a single arm study&#xD;
Conjugated Linolenic Acid (CLA)- daily oral dose 3 g/day&#xD;
Sodium Nitrate- Capsules for daily oral administration at the dose of 1 g (2 x 500 mg)&#xD;
Sodium Nitrite- Capsules for daily oral administration at the dose of 20 mg (2 x 10 mg)&#xD;
Conjugated Linolenic Acid: CLA is a polyunsaturated fatty acid Subjects will receive capsules for daily oral administration at the dose of 3 g/day&#xD;
Sodium Nitrite: Subjects will receive capsules for daily oral administration at the dose of 20 mg (2 x 10 mg)&#xD;
Sodium Nitrate: Subjects will receive capsules for daily oral administration at the dose of 1g (2 x 500 mg)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Stacy Gelhaus Wendell</name_or_title>
      <organization>University of Pittsburgh</organization>
      <phone>412-648-1351</phone>
      <email>gstacy@pitt.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

